Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Incheon St.Mary's Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Varian, a Siemens Healthineers Company
Novartis
EMD Serono
Toros University
AstraZeneca
Pfizer
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
AstraZeneca
Boehringer Ingelheim
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Travera Inc
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
University Health Network, Toronto
Jazz Pharmaceuticals
Fred Hutchinson Cancer Center
Novartis
Bayer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Alliance for Clinical Trials in Oncology
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Shanghai Zhongshan Hospital